Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions

NCT01003106 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

81

Enrollment

OTHER

Sponsor class

Conditions

Retinal Vein Occlusion

Interventions

DRUG: Ranibizumab 0.5mg (monthly)
DRUG: Ranibizumab 2.0mg (monthly)
DRUG: Pro re nata (prn) ranibizumab
PROCEDURE: Pro re nata (prn) Laser photocoagulation

Sponsor

Peter A Campochiaro, MD

Collaborators

[object Object]